Singapore
Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics
Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
ASLAN Pharmaceuticals announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares.
Flagship expands into Asia-Pacific with new Singapore hub
Biotechnology company creator Flagship Pioneering is expanding its global footprint, announcing Tuesday the establishment of a regional hub in Singapore.
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
“ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore,” said Alice Chen, Executive Vice President at ALSP and Automera board member.
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
The ADSs are expected to begin trading on the Nasdaq Global Market on September 29, 2023 under the ticker symbol “ANL”.
Temasek sees ‘very attractive’ investments in China’s emerging sectors
The Singaporean state investor remains optimistic about China despite economic and geopolitical headwinds.
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis. Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL
AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced it has successfully raised US$20+ million in Series B funding.
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
ACM Biolabs, a biotechnology company using its next-generation polymer-based delivery platform to develop new nano formulations for use in multiple therapeutic fields, today announced positive topline results from a Phase I trial of ACM-001, the Company's first clinical-stage development program.
Specialised Therapeutics acquires commercialisation rights to new oral MND therapy
Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis (ALS) – the most common form of Motor Neurone Disease (MND) - in Australia and New Zealand.
